MERCK CMV MK-8228 LET (Kidney Transplant) - Clinical Trial

What is the Purpose of this Study?

If you choose to join this study, you will:
- Be randomized (like flipping a coin) to Group 1 or Group 2
-- Group 1 will get the study drug, Letermovir (LET)
-- Group 2 will get the standard of care medicine, Valganciclovir (VGCV)
- Both groups will also be asked to give blood

What is the Condition Being Studied?

Kidney Transplant

Who Can Participate in the Study?

Adults who:
- Have had or will have a kidney transplant within 7 days of signing up for the study

Age Group
Adults

What is Involved?

We are doing this study to learn more about the study drug (Letermovir) and how it can help keep people from getting Human Cytomegalovirus (CMV) disease.

Study Details

Full Title
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients
Principal Investigator
Kidney/Pancreas Transplant Surgeon
Protocol Number
IRB: PRO00090050
NCT: NCT03443869
Phase
Phase III
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698